<DOC>
	<DOC>NCT02490514</DOC>
	<brief_summary>This open-label, non-randomized, retrospective-prospective, non-interventional study will evaluate the efficacy and safety of Mircera in patients with stage III-IV chronic kidney disease (CKD) not on dialysis. Patients will receive open-label treatment with Mircera for 12 months at a dose to be determined by the investigator.</brief_summary>
	<brief_title>A Study Of Mircera In Patients With Kidney Disease Who Are Not On Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Acidosis</mesh_term>
	<mesh_term>Anemia, Hemolytic</mesh_term>
	<mesh_term>Acidosis, Renal Tubular</mesh_term>
	<criteria>Patients with stage IIIV CKD not on dialysis, including renal transplant patients, who are receiving erythropoiesisstimulating agent (ESA) treatment or are ESAnaive Patients who will not require dialysis within 12 months after the start of Mircera therapy Patients whose life expectancy is greater than 12 months after Mircera initiation Patients &gt;/= 18 years and &lt;/= 75 years of age Patients who are female and of childbearing potential must be using effective contraception methods Patients with no contraindications to ESA treatment (for example, hypersensitivity, noncontrolled hypertension and others according to the local SmPC) Patients who have given written informed consent where local regulations allow or require it Patients with stage III or stage V CKD Poorly controlled hypertension Active malignant disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>